AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34130339
Drug: Aspirin for
RxNorm normalized name: Aspirin 81 MG Oral Tablet, Chewable [ASPIRIN FOR CHILDREN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin for reducing the risk of colorectal cancer and other types of cancer
Trial: 37294477
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen
Trial: 33779383
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of THC
Trial: 35478399
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with orphan drug designation
Trial: 34886880
Drug: ragweed SLIT-tablet
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ragweed SLIT-tablet (12 Amb a 1-U)
Trial: 35307068
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medicine (octreotide + symptomatic treatment)
Trial: 32115639
Drug: Pulse dose
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse dose technique (Yttrium)
Trial: 32115639
Drug: Fresh-cut perennial
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fresh-cut perennial ryegrass (Lolium perenne L.)
Trial: 33477158
Drug: Argatroban injection
RxNorm normalized name: argatroban Injection
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban injection 60 mg intravenously for 2 days, then 10 mg bid for 5 days (total 7 days)
Trial: 32425024
Drug: Ultrasonic technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic technique for implant site preparation
Trial: 36322033
Drug: Subarachnoid anaesthesia
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid anaesthesia with morphine and bupivacaine (SAB)
Trial: 32446832
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5% QD
Trial: 32446832
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1% QD
Trial: 32446832
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 0.5% BID
Trial: 32446832
Drug: Tapinarof cream
RxNorm normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream 1% BID
Trial: 32482645
Drug: csDMARD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: csDMARD tapering first
Trial: 32482645
Drug: TNF-inhibitor tapering
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-inhibitor tapering first
Trial: 33642167
Drug: Beta-blockers in
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers in patients with LVEF ≤40%
Trial: 33642167
Drug: Beta-blockers in
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers in patients with LVEF >40%
Trial: 32166534
Drug: Desmopressin (dDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (dDAVP) administered intravenously in doses from 0.25 to 2.0 µg/kg over two consecutive days.
Trial: 32166534
Drug: Desmopressin (dDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (dDAVP) treatment.
Trial: 32394228
Drug: Lixisenatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (20 μg single-dose injection)
Trial: 36351926
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of CaCO3
Trial: 36351926
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of CaCO3
Trial: 36351926
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of CaCO3
Trial: 36351926
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of CaCO3
Trial: 36351926
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of CaCO3
Trial: 36351926
Drug: Genotype I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype I and 5 g of CaCO3
Trial: 33271534
Drug: Plasma magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma magnesium concentrations in quartile 1 (<0.76 mmol/L)
Trial: 33271534
Drug: Plasma magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma magnesium concentrations in quartile 4 (≥0.89 mmol/L)
Trial: 33271534
Drug: Plasma magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma magnesium concentrations in quartile 3 (0.83 to <0.89 mmol/L)
Trial: 32833845
Drug: Nonprogressive KCN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprogressive KCN group (serum vitamin D levels: 12.77 ± 5.52 ng/mL)
Trial: 32833845
Drug: Progressive KCN
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive KCN group (serum vitamin D levels: 11.78 ± 4.32 ng/mL)
Trial: 32833845
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (serum vitamin D levels: 17.40 ± 5.12 ng/mL)
Trial: 36214945
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (exact dosage and duration not specified)
Trial: 33143931
Drug: Goal-directed hemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hemodynamic therapy
Trial: 33143931
Drug: Restrictive normovolemic
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive normovolemic therapy
Trial: 32312645
Drug: Cemented femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented femoral and tibial implants
Trial: 32312645
Drug: Cemented tibial
RxNorm normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented tibial implant, uncemented femoral implant (hybrid group)
Trial: 39018515
Drug: Tailored dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose-dense chemotherapy
Trial: 36052473
Drug: 3-components phytotherapic
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-components phytotherapic composed of Herniaria hirsuta and Peumus boldus plus water oral intake for 12 days/month over 3 months (Group A)
Trial: 33851854
Drug: Follow-up/future treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up/future treatment costs
Trial: 34507244
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy (fluoropyrimidine, bevacizumab, irinotecan)
Trial: 32093741
Drug: Lactocare (ZistTakhmir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactocare (ZistTakhmir) capsules 500 mg every 12 hours for 14 days
Trial: 32093741
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule containing only sterile maize starch, similar to synbiotic capsules for 14 days
Trial: 32316886
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment for insomnia (one group session of sleep hygiene education and four individual sessions of counseling)
Trial: 32978842
Drug: Novel antibiotic-free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel antibiotic-free film-forming silicone-based wound dressing
Trial: 32978842
Drug: Topical triple
RxNorm normalized name: Triple Paste Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triple antibiotic petrolatum-based ointment
Trial: 33357512
Drug: Riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50 mg twice a day for 14 days before surgery and then for 28 days after surgery)
Trial: 35321888
Drug: Completion surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion surgery followed by an additional five cycles of chemotherapy (control arm)
Trial: 35321888
Drug: An additional
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An additional three cycles of neoadjuvant chemotherapy followed by completion surgery and then two additional cycles of chemotherapy (experimental arm)
Trial: 32927371
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure treatment
Trial: 32927371
Drug: Non-exposure based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exposure based treatment
Trial: 33657450
Drug: SSRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI treatment (10mg escitalopram)
Trial: 34510501
Drug: Average Treatment
RxNorm normalized name: immune globulin,alpha (IgA) average 46 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average Treatment Effect (ATE)
Trial: 34227392
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with drug-eluting stents
Trial: 35151504
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg)
Trial: 34278042
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day orally for 90 days
Trial: 33601121
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vitamin A (2000 IU/d) and Vitamin D (400 IU/d)
Trial: 33601121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tuberculosis treatment only)
Trial: 34755627
Drug: Maralixibat 380
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat 380 μg/kg once per day for 18 weeks, followed by random assignment to continue maralixibat or receive placebo for 4 weeks.
Trial: 34755627
Drug: Maralixibat continued
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat continued treatment
Trial: 34755627
Drug: Maralixibat continued
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat continued treatment until week 204
Trial: 33483613
Drug: IM 400
RxNorm normalized name: Bactrim 400mg-80mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM 400 mg
Trial: 33483613
Drug: IM 600
RxNorm normalized name: Anthim 600 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM 600 mg
Trial: 33483613
Drug: IM 400
RxNorm normalized name: Bactrim 400mg-80mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM 400 mg + cytarabine (AraC)
Trial: 33483613
Drug: IM 400
RxNorm normalized name: Bactrim 400mg-80mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM 400 mg + pegylated interferon alpha2a (PegIFN‐α2a)
Trial: 35472008
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg twice daily)
Trial: 34494323
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g low-fat milk powder (placebo)
Trial: 35468621
Drug: F16IL2 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F16IL2 (10 × 10^6 to 20 × 10^6 IU IV; days 1, 8, 15, and 22 of each 28‐day cycle) + BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion)
Trial: 35283262
Drug: Anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory drug for heart failure
Trial: 32347934
Drug: Olaparib 150
RxNorm normalized name: olaparib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 150 mg (3 days/week) with TMZ 75 mg/m2 daily for 42 days
Trial: 36227220
Drug: Tailored nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored nutritional dietary rehabilitation plan including dietary supplements
Trial: 34916320
Drug: Dose-intense regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intense regimen of doxorubicin and cisplatin
Trial: 32898170
Drug: Intramuscular stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular stimulation with a 12-week rehabilitation program (n = 25)
Trial: 32898170
Drug: Sham intramuscular
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham intramuscular stimulation with a 12-week rehabilitation program (n = 19)
Trial: 34499574
Drug: Recombinant rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant rabies G protein vaccine
Trial: 34499574
Drug: Reference vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference vaccine (five-dose WHO prequalified vaccine)
Trial: 32744902
Drug: Secretion above
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretion above 25 mL (drainage longer than 24 hours)
Trial: 32744902
Drug: Secretion below
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secretion below 25 mL (drainage less than 24 hours)
Trial: 34305584
Drug: Elaeagnus angustifolia
RxNorm normalized name: ELAEAGNUS ANGUSTIFOLIA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elaeagnus angustifolia (15 g of the whole fruit powder)
Trial: 34305584
Drug: Placebo (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7.5 g isomalt + 7.5 g cornstarch)
Trial: 34086524
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of kinesiotaping and stretching
Trial: 35170783
Drug: Melatonin 10
RxNorm normalized name: melatonin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 10 mg administered every night for 24 weeks
Trial: 35170783
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every night for 24 weeks
Trial: 34369908
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Trial: 34369908
Drug: Efavirenz 600
RxNorm normalized name: efavirenz 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz 600 mg four times a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Trial: 34598676
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Trimetazidine (TMZ) 12 hours before surgery
Trial: 32102086
Drug: Fezolinetant 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fezolinetant 15, 30, 60, 90 mg BID or 30, 60, 120 mg QD
Trial: 34373282
Drug: Cabazitaxel chemotherapy
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel chemotherapy
Trial: 34634757
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention to reduce sedentary behaviour, details on dosage and duration not specified.
Trial: 34106974
Drug: Problem-solving skills
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving skills intervention delivered through 6 monthly sessions
Trial: 33400348
Drug: Topiroxostat 40–160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 40–160 mg/day
Trial: 33400348
Drug: Febuxostat 10–60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 10–60 mg/day
Trial: 33221788
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during the same period)
Trial: 34303445
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment conditions
Trial: 34399847
Drug: CBT‐VR (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐VR (Cognitive Behavioural Therapy and Vestibular Rehabilitation)
Trial: 36179772
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence to oral anticoagulants (OACs) defined as proportion of days covered (PDC) >80%
Trial: 33865507
Drug: Ravidasvir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravidasvir (200 mg once daily) plus Sofosbuvir (400 mg once daily) for 12 weeks (no cirrhosis) or 24 weeks (with cirrhosis)
Trial: 35466343
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (transducer on intravenous pole)
Trial: 35507912
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination with 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule (schedule 2 group)
Trial: 39514041
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Trial: 38802635
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg
Trial: 32314514
Drug: Aloe extract
RxNorm normalized name: aloe extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe extract treatment for 4 weeks
Trial: 32314514
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (inulin) for 4 weeks
Trial: 32314514
Drug: Aloe treatment
RxNorm normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe treatment responders (n = 33, 39%)
Trial: 32314514
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment responders (n = 34, 45%)
Trial: 35821950
Drug: Preoperative educational
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative educational video and postoperative acceptance and commitment therapy (ACT)
Trial: 32334553
Drug: Self-administered drug
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered drug intake supported by a family member
Trial: 33356422
Drug: Irinotecan and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan and cetuximab with vemurafenib (960 mg PO twice daily)
Trial: 33243018
Drug: Quxie capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quxie capsule (QX) treatment
Trial: 34470831
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (100 mg biweekly, total 2 g over 40 weeks)
Trial: 34470831
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (500 mg every 10 weeks, total 2 g over 40 weeks)
Trial: 34470831
Drug: Erythropoiesis-stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agent use
Trial: 34965603
Drug: Absorbable nasal
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable nasal implant
Trial: 32318809
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg single dose
Trial: 36227659
Drug: mPEG-HA-Pt treatment
RxNorm normalized name: MPEG 6000 acetyl lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mPEG-HA-Pt treatment